Emerging antibodies for the treatment of pancreatic cancer. (Q39158427)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

title

Emerging antibodies for the treatment of pancreatic cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Kalliopi Andrikou

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Chiara Peterle

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Stefania Pipitone

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

Massimiliano Salati

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

language of work or name

English

0 references

publication date

28 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

4 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

page(s)

39-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

Pancreatic Adenocarcinoma

4 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

European cancer mortality predictions for the year 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Risk factors for pancreatic cancer: a summary review of meta-analytical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

21 January 2018

Cancer statistics, 2016

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Oncogenic KRAS signalling in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

HER2 overexpression correlates with survival after curative resection of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

IGF-1R as an anti-cancer target--trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

The Notch pathway in cancer: differentiation gone awry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

PD-L1 expression in human cancers and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Genomic analyses identify molecular subtypes of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Ex vivo expanded telomerase-specific T cells are effective in an orthotopic mouse model for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728214.2017.1293649

10.1080/14728214.2017.1293649

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json

4 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28253833%20AND%20SRC:MED&resulttype=core&format=json